Habib N A, Hershman M J, Smadja C, Wood C B
Br J Surg. 1986 Sep;73(9):758-9. doi: 10.1002/bjs.1800730927.
The value of a radioimmunoassay (RIA) in the detection of the human carcinoma-associated antigen CA-50 has been assessed in 50 normal subjects, 28 patients with various benign liver diseases and 91 patients with primary and secondary liver carcinomas. Sera from all normal subjects and 25 of 28 (89 per cent) patients with benign liver diseases had a CA-50 level below 17 units/ml. Three patients with sclerosing cholangitis and sixty (66 per cent) patients with primary or secondary liver tumours had CA-50 levels above 17 units/ml. CA-50 may therefore be a useful tumour marker for the diagnosis of liver carcinomas and for the post-treatment monitoring of patients with various liver malignancies.
在50名正常受试者、28名患有各种良性肝病的患者以及91名原发性和继发性肝癌患者中，评估了放射免疫分析（RIA）检测人癌相关抗原CA - 50的价值。所有正常受试者以及28名良性肝病患者中的25名（89%）血清CA - 50水平低于17单位/毫升。3名硬化性胆管炎患者以及60名（66%）原发性或继发性肝肿瘤患者的CA - 50水平高于17单位/毫升。因此，CA - 50可能是诊断肝癌以及对各种肝脏恶性肿瘤患者进行治疗后监测的有用肿瘤标志物。
